Synergistic effects of INTERCEED(TC7) and heparin in reducing adhesion formation in the rabbit uterine horn model
- M. P. Diamond(corresponding author),
- C. B. Linsky,
- T. Cunningham,
- L. Kamp,
- E. Pines,
- A. H. DeCherney
- Yale University
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Abstract
<p>Surgical adjuvants are commonly employed to reduce the frequency of postoperative adhesion development after reproductive pelvic surgery. The ability of indomethacin, promethazine, dexamethasone, Intralipid, progesterone, and heparin to reduce adhesion formation in combination with INTERCEED(TC7) (Johnson and Johnson Medical, Inc., New Brunswick, NJ), an absorbable barrier that alone reduces adhesion formation, was examined in a rabbit uterine horn model. A significant reduction in adhesion formation was only observed with the combination of INTERCEED(TC7) plus heparin. In additional studies, heparin delivery by intraperitoneal (IP) lavage, intravenous injection, or intra-abdominal instillation failed to demonstrate efficacy. Similarly, heparin delivery with other barriers or IP instillates (carboxymethylcellulose or 32% Dextran 70) failed to reduce adhesion formation. We conclude that INTERCEED(TC7) can be efficaciously utilized as a carrier to deliver heparin to traumatized surfaces, thereby reducing adhesion formation.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 389-394 (6 pages)Journal (Volume, Issue Number)
Fertility and sterility (Volume 55, Issue 2)Publication milestones
- Published - 1991
Publication status
Published - 1991
ISSN
0015-0282Publication IDs
- Scopus: 0026092521
- PubMed: 1991536
- ORCID: /0000-0001-6353-4489/work/227032863
Publication metrics
Metrics
Fractional count
1
Fractional count
0.14
Fractional count
6
Fractional count
0.86
Fractional count
1
Fractional count
1
PlumX, opens in new tab
Citation count
83
Captures
5
Funding Details
Received March 15, 1990; revised and accepted August 16, 1990. * Johnson and Johnson Medical, Inc., New Brunswick, New Jersey. t Presented in part at the 43rd Annual Meeting of The American Fertility Society, Reno, Nevada, September 28 to 30, 1987; and at the 73rd Annual Meeting of The American College of Surgeons, San Francisco, California, October 11 to 16,1987. :j: Supported by Johnson and Johnson Medical, Inc., New Brunswick, New Jersey. § Department of Obstetrics and Gynecology, Yale University School of Medicine. II Recipient of the Clinical Associate Physician Award of the Yale General Clinical Research Center of the National Institutes of Health, Bethesda, Maryland. [ Reprint requests: Michael P. Diamond, M.D., Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Yale University School of Medicine, 333 Cedar Street, P. O. Box 3333, New Haven, Connecticut 06510. # Johnson and Johnson Medical, Inc., New Brunswick, New Jersey. ** Department of Obstetrics and Gynecology, University of Southern California Medical Center.
FunderFunding numbers
J&J
-